Peer-reviewed veterinary case report
Vomiting risk in cats on long-term piroxicam for tumors
By Bulman-Fleming, Julie C et al.·Published in Journal of feline medicine and surgery·2010·Veterinary Cancer Group, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms.
- Species:
- cat
Plain-English summary
A group of 73 cats receiving long-term daily piroxicam, a medication often used for cancer treatment, experienced some side effects, particularly vomiting, especially in those also undergoing chemotherapy. Most adverse reactions were mild and temporary, with only a small percentage of cats needing to stop the medication due to these issues. Overall, piroxicam was found to be well tolerated in cats over the course of treatment lasting from 1 to 38 months, without significant harm to their blood, kidneys, or liver.
People also search for: cat vomiting after piroxicam · long-term piroxicam side effects in cats · cat cancer treatment medication · piroxicam for cats with tumors
Abstract
The role of cyclo-oxygenase 2 (COX-2) and prostaglandins (PG) in carcinogenesis has been documented in many species. Piroxicam has shown efficacy against several neoplasms and is frequently prescribed for chronic use. There are no studies investigating chronic piroxicam administration in cats and the chronic use of non-steroidal anti-inflammatory agents in this species has long been cautioned against. This retrospective study aimed to evaluate adverse effects in cats receiving long-term daily piroxicam. Seventy-three cats received daily piroxicam at doses of 0.13-0.41mg/kg. Treatment duration ranged from 1 to 38 months. Treatment with piroxicam was found to significantly increase frequency of vomiting during the first month of therapy, though this was most significant for cats receiving concurrent chemotherapy. Piroxicam administration was not significantly associated with hematologic, renal or hepatic toxicities. Adverse events were not correlated with dosage. Adverse events were reported in 29% of cats, and were generally mild and transient. Eight percent discontinued piroxicam due to adverse reaction, and 4% due to difficult administration. This study indicates that long-term daily piroxicam is generally well tolerated in cats at conventional doses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20363461/